Novartis Not Tempted To Join COVID-19 Vaccines Race
No Longer Has Capabilities After GSK Asset Swap
While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.
You may also be interested in...
Latest clinical results show that CanSino's adeno-associated virus coronavirus vaccine appears to be safe and that it induced an immune response in most subjects.
While data from small trials are difficult to compare, it appears that T-cell responses to BNT162b1 may be stronger than those reported so far for Moderna’s competing mRNA-based vaccine.
Oxford’s long-awaited early stage study produces solid safety and efficacy results, but lags Pfizer/BioNTech and Moderna’s mRNA candidates for antibody response.